With the $18 billion allergy and eczema blockbuster losing patent protection in 2031, the partners are betting on four long-acting antibodies that hit the same pathways with far fewer injections.
Bristol Myers Squibb’s heart drug becomes the first of its class approved for adolescents with the inherited condition, a leading cause of sudden cardiac death in young people.
The deal, worth up to $2.6 billion, gives Novo an early-stage oral GLP-1/GIP drug designed to be taken once a week — a bid to leapfrog today’s daily pills as its rivalry with Lilly intensifies.
Both remove amyloid from the brain and modestly slow early Alzheimer’s. They differ in how they are given, how long treatment lasts, the risk of brain swelling, and cost — differences that matter when choosing.
The drugmaker is buying a stake in the developer of the bispecific antibody that beat Keytruda in a lung cancer trial, and will test it alongside its antibody-drug conjugates in gastrointestinal cancers.
TrumpRx.gov lists discounted cash prices for brand-name drugs, including GLP-1s such as Zepbound, Wegovy and Ozempic. Here is how it works, what the prices are, and when it is — and isn’t — the cheapest option.
Children with idiopathic nephrotic syndrome have relied on steroids since the 1950s. Roche’s obinutuzumab is now approved to keep frequently relapsing patients in remission — offering a way off repeated steroid courses.
Tavapadon targets a narrower set of dopamine receptors than older drugs, aiming to ease movement symptoms with fewer of the side effects that make dopamine agonists hard to tolerate.
Lilly’s triple-hormone drug produced some of the largest weight loss ever seen in obesity trials. It isn’t approved yet — and a fast-growing online market selling it as a “research peptide” carries real dangers.
A University of Florida study of health records found people with memory problems who took glucosamine were more likely to progress to dementia. It is an association, not proof — but mouse experiments point to a plausible mechanism.
CRISPR Therapeutics’ CTX310 switches off the ANGPTL3 gene in the liver. One-year follow-up in a small first-in-human trial shows LDL and triglycerides stayed down with no serious treatment-related side effects.
Efsitora alfa turns 365 basal insulin injections a year into 52. It is the second weekly insulin cleared in the US this year — and a sign that diabetes care is shifting toward fewer, longer-acting doses.